Related Experiment Videos
Obesity: drugs and dietary supplements
Jennifer M Vesely1, Laure G DeMattia2
1Park Nicollet Bariatric Surgery Center, 3931 Louisiana Ave. S., St. Louis Park, MN 55426, jennifer.vesely@parknicollet.com.
FP Essentials
|October 18, 2014
Summary
Pharmacotherapy is recommended for obesity management when lifestyle changes are insufficient. Effective weight loss drugs require ongoing assessment, with discontinuation if 5% weight loss isn
Area of Science:
- Obesity Medicine
- Pharmacology
- Metabolic Disorders
Background:
- Lifestyle interventions are primary for obesity management.
- Pharmacotherapy is indicated for individuals with a body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities.
- Obesity involves complex neurohormonal dysregulation often requiring long-term management.
Purpose of the Study:
- To outline the role of pharmacotherapy in comprehensive obesity management.
- To provide guidance on the selection, trial, and discontinuation of obesity medications.
- To clarify the limited role of supplements and integrative therapies in long-term obesity control.
Main Methods:
- Review of current guidelines and clinical trial data on obesity pharmacotherapy.
- Analysis of drug efficacy based on percentage of weight loss.
- Consideration of drug-induced weight gain and alternative therapeutic options.
Main Results:
- Obesity medications should be considered for long-term use to manage underlying neurohormonal issues.
- A minimum of 5% weight loss within 12 weeks is a benchmark for drug effectiveness.
- Discontinuation or modification of therapy is recommended if efficacy is not met or if weight gain occurs.
Conclusions:
- Pharmacotherapy is a valuable tool in obesity management when combined with lifestyle interventions.
- Individualized treatment plans are necessary, potentially involving trials of multiple medications.
- Dietary supplements and integrative therapies lack evidence for long-term obesity management efficacy.